Decreased eukaryotic initiation factors expression upon temozolomide treatment—potential novel implications for eIFs in glioma therapy

被引：0

作者：

Stefanie Krassnig

Stefan L. Leber

Andrea Orthmann

Nicole Golob-Schwarzl

Heinrich Johann Huber

Christina Wohlrab

Christina Skofler

Mirjam Pennauer

Andrea Raicht

Anna Maria Birkl-Toeglhofer

Michael Naumann

Kariem Mahdy-Ali

Gord von Campe

Marlene Leoni

Joshua Alcaniz

Jens Hoffmann

Thomas Wälchli

Serge Weis

Martin Benesch

Johannes Haybaeck

机构：

[1] Medical University of Graz,Diagnostic & Research Center for Molecular BioMedicine, Department of Neuropathology, Institute of Pathology

[2] EPO Berlin Buch GmbH,Drug Discovery Sciences, Dr. Boehringer Gasse 5

[3] Center for Biomarker Research in Medicine,11 A

[4] Boehringer Ingelheim RCV GmbH & Co KG,1121

[5] Medical University of Innsbruck,Department of Pathology

[6] Medical University of Graz,Division of Paediatric Haematology and Oncology, Department of Paediatrics and Adolescent Medicine

[7] Medical University of Graz,Department of Neurosurgery

[8] Kepler University Hospital,Division of Neuropathology

[9] Johannes Kepler University,Department of Pathology, Medical Faculty

[10] Otto-von-Guericke University Magdeburg,Division of Neuroradiology, Vascular & Interventional Radiology, Department of Radiology

[11] German Center for Neurodegenerative Diseases (DZNE),Group of CNS Angiogenesis and Neurovascular Link, Neuroscience Center Zurich, Division of Neurosurgery

[12] Medical University of Graz,Division of Neurosurgery

[13] University and University Hospital Zurich,Group Brain Vasculature and Perivascular Niche, Division of Experimental and Translational Neuroscience, Krembil Brain Institute, Toronto Western Hospital, University Health Network

[14] University Hospital Zurich,Division of Neurosurgery, Department of Surgery, Toronto Western Hospital

[15] Krembil Research Institute,Institute of Experimental Internal Medicine

[16] University of Toronto,undefined

[17] University of Toronto,undefined

[18] Otto Von Guericke University,undefined

来源：

Journal of Neuro-Oncology | 2023年 / 165卷

关键词：

Astrocytoma; Glioma; Eukaryotic initiation factors; Temozolomide; Glioma therapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：91 / 100

页数：9

共 14 条

[1] Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy
Krassnig, Stefanie
Leber, Stefan L.
Orthmann, Andrea
Golob-Schwarzl, Nicole
Huber, Heinrich Johann
Wohlrab, Christina
Skofler, Christina
Pennauer, Mirjam
Raicht, Andrea
Birkl-Toeglhofer, Anna Maria
Naumann, Michael
Mahdy-Ali, Kariem
von Campe, Gord
Leoni, Marlene
Alcaniz, Joshua
Hoffmann, Jens
Waelchli, Thomas
Weis, Serge
Benesch, Martin
Haybaeck, Johannes
JOURNAL OF NEURO-ONCOLOGY, 2023, 165 (01) : 91 - 100
[2] Eukaryotic Translation Initiation Factors (eIFs): Potential therapeutic targets in psoriasis
Golob-Schwarzl, N.
Pilic, J.
Benezeder, T.
Painsi, C.
Wolf, P.
EXPERIMENTAL DERMATOLOGY, 2021, 30 : 5 - 6
[3] Eukaryotic Translation Initiation Factors (eIFs): Potential Therapeutic Targets in Psoriasis
Golob-Schwarzl, N.
Pilic, J.
Benezeder, T.
Painsi, C.
Wolf, P.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (10) : S177 - S177
[4] GENE EXPRESSION OF EUKARYOTIC INITIATION FACTORS UPON PROBIOTIC ADMINISTRATION IN DEPRESSIVE PATIENTS
Birkl-Toeglhofer, Anna Maria
Bengesser, Susanne
Rieger, Alexandra
Fellendorf, Frederike
Platzer, Martina
Queissner, Robert
Hamm, Carlo
Maget, Alexander
Moerkl, Sabrina
Wagner-Skacel, Jolana
Schwarzbraun, Thomas
Haybaeck, Johannes
Reininghaus, Eva
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : 1232 - 1232
[5] Eukaryotic initiation factors might not only represent novel targets for glioma therapies but might also monitor drug effectiveness
Krassnig, S.
Orthmann, A.
Toeglhofer, A. M.
Wohlrab, C.
Golob-Schwarzl, N.
Wodlej, C.
Pennauer, M.
Raicht, A.
Ali, K. Mahdy
von Campe, G.
Gogg-Kamerer, M.
Logi, M.
Sygulla, S.
Hoffmann, J.
Weis, S.
Benesch, M.
Haybaeck, J.
VIRCHOWS ARCHIV, 2017, 471 : S46 - S46
[6] A Profound Basic Characterization of eIFs in Gliomas: Identifying eIF3I and 4H as Potential Novel Target Candidates in Glioma Therapy
Krassnig, Stefanie
Wohlrab, Christina
Golob-Schwarzl, Nicole
Raicht, Andrea
Schatz, Christoph
Birkl-Toeglhofer, Anna Maria
Skofler, Christina
Gantenbein, Nadine
Leoni, Marlene
Asslaber, Martin
Leber, Stefan L.
Mahdy-Ali, Kariem
von Campe, Gord
Mayer, Marlene
Borenich, Andrea
Weis, Serge
Benesch, Martin
Haybaeck, Johannes
CANCERS, 2021, 13 (06)
[7] Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy
Miguel Garcia-Menaya, Jesus
Cordobes-Duran, Concepcion
Garcia-Martin, Elena
Agundez, Jose A. G.
FRONTIERS IN PHARMACOLOGY, 2019, 10
[8] Diminished milk synthesis in upstream stimulatory factor 2 null mice is associated with decreased circulating oxytocin and decreased mammary gland expression of eukaryotic initiation factors 4E and 4G
Hadsell, DL
Bonnette, S
George, J
Torres, D
Klementidis, Y
Gao, S
Haney, PM
Summy-Long, J
Soloff, MS
Parlow, AF
Sirito, M
Sawadogo, M
MOLECULAR ENDOCRINOLOGY, 2003, 17 (11) : 2251 - 2267
[9] Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent
Uram, Lukasz
Markowicz, Joanna
Misiorek, Maria
Filipowicz-Rachwal, Aleksandra
Wolowiec, Stanislaw
Walajtys-Rode, Elzbieta
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 152
[10] On the effect of transient expression of mutated eIF2α and eIF4E eukaryotic translation initiation factors on reporter gene expression in mammalian cells upon cold-shock
Underhill, Michele F.
Marchant, Rosalyn J.
Carden, Martin J.
James, David C.
Smales, C. Mark
MOLECULAR BIOTECHNOLOGY, 2006, 34 (02) : 141 - 149

← 1 2 →